Journal
CANCER CELL
Volume 30, Issue 2, Pages 197-213Publisher
CELL PRESS
DOI: 10.1016/j.ccell.2016.07.006
Keywords
-
Categories
Funding
- Charles Revson Senior Fellowship in Biomedical Science
- American Society of Hematology Scholar Award
- NIH [5F30HL093996, 5T32GM008244]
- AHA [0810194Z]
- University of Minnesota Wetzel Fund
- NCI [R01 CA071540, R01 CA187109]
- Minnesota Masonic Charities
- University of Minnesota Medical School and Office of the Vice President for Research
- LLS TRP [6141-14]
- Janssen
- Eli Lilly
- GSK
- Roche
Ask authors/readers for more resources
The EZH2 histone methyltransferase mediates the humoral immune response and drives lymphomagenesis through formation of bivalent chromatin domains at critical germinal center (GC) B cell promoters. Herein we show that the actions of EZH2 in driving GC formation and lymphoma precursor lesions require site-specific binding by the BCL6 transcriptional repressor and the presence of a non-canonical PRC1-BCOR-CBX8 complex. The chromodomain protein CBX8 is induced in GC B cells, binds to H3K27me3 at bivalent promoters, and is required for stable association of the complex and the resulting histone modifications. Moreover, oncogenic BCL6 and EZH2 cooperate to accelerate diffuse large B cell lymphoma (DLBCL) development and combinatorial targeting of these repressors results in enhanced anti-lymphoma activity in DLBCLs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available